echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Voice of China: The first domestic PD-1 inhibitor combined with double platinum chemotherapy for neoadjuvant treatment of stage IIB-IIIB NSCLC is safe and effective!

    Voice of China: The first domestic PD-1 inhibitor combined with double platinum chemotherapy for neoadjuvant treatment of stage IIB-IIIB NSCLC is safe and effective!

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    PD-1 inhibitors have shown potential antitumor activity in non-small cell lung cancer (NSCLC.


    This study included patients with stage IIB-IIIB, EGFR/ALK wild-type NSCLC with ECOG PS 0-1 statu.


    A total of 53 eligible patients (median age: 62 years, IQR: 45-76; women: 5, 4%, squamous cell carcinoma: 42, 72%) receiving 2-4 cycles of neoadjuvant starting March 2021 treatmen.


    46 cases (46/499,99%) of grade 1-2 tra.


    Neoadjuvant therapy with toripril combined with platinum-doublet chemotherapy is a promising, tolerable and effective approach for the treatment of stage IIB-IIIB non-small cell lung cance.


     

    Original source:

    Abstract number: 2105

    Neoadjuvant Toripalimab combination in patients with stage IIB-IIIB NSCLC: a single-arm, phase 2 trial (Renaissance Study)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.